Sweden’s Affibody Inks Inmagene China R&D Pact

Affibody And Inmagene Will Focus On Auto-Immune Diseases

Swedish biotech Affibody hopes an R&D alliance with China-based Inmagene Biopharmaceuticals will speed development of its lead compound for auto-immune diseases.

China_Sweden_Coins
Duo aim to commercialize ABY-035 targeting IL-17 • Source: Shutterstock

Affibody AB of Sweden and Inmagene Biopharmaceuticals Ltd. of China have entered a strategic partnership to develop and commercialize the Swedish biotech’s lead asset, a bispecific molecule targeting Interleukin-17A for multiple auto-immune diseases that could be on the market within six years.

Their alliance, announced on 15 May, focuses on Affibody’s ABY-035, an innovative fusion protein that is in Phase II development...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.